Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →🤖 ML Fraud Detection Score: 90%
Machine learning model identifies prescribing patterns consistent with confirmed fraud cases. This is a statistical indicator, not an accusation.
Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
2,151
Total Claims
$5.5M
Drug Cost
344
Beneficiaries
$16K
Cost/Patient
Risk Score Breakdown 12/100
Score components are additive. Read full methodology
Peer Comparison vs. 8,541 Hematology-Oncology providers
+96%
Opioid rate vs peers
12.3% vs 6.3% avg
+17%
Cost per patient vs peers
$16K vs $14K avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
ML fraud detection score of 90% indicates prescribing patterns with significant similarity to confirmed fraud cases. 18 out of 20 decision trees flagged this provider.
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
12.3%
Opioid Rate
265
Opioid Claims
$12K
Opioid Cost
26.0%
Long-Acting Rate
Brand vs Generic
Brand: 0 claims · $0
Generic: 1,495 claims · $317K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Enzalutamide | 39 | $499K |
| Lenvatinib Mesylate | 18 | $477K |
| Pomalidomide | 23 | $472K |
| Enasidenib Mesylate | 13 | $434K |
| Venetoclax | 30 | $376K |
| Osimertinib Mesylate | 15 | $353K |
| Lenalidomide | 18 | $330K |
| Selpercatinib | 11 | $263K |
| Apalutamide | 19 | $256K |
| Alectinib Hcl | 12 | $244K |
| Ixazomib Citrate | 21 | $221K |
| Everolimus | 19 | $190K |
| Apixaban | 175 | $140K |
| Trifluridine/Tipiracil Hcl | 20 | $133K |
| Abiraterone Acetate | 17 | $80K |
Prescribing Profile
Patient Profile
72
Avg Age
54%
Female
2.58
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About